Objective: Cognitive difficulties are common in epilepsy. Beyond reducing seizures and adjusting antiepileptic medications, no well-validated treatment exists in adults. Methylphenidate is used effectively in children with epilepsy and attention-deficit/ hyperactivity disorder, but its effects in adults have not been systematically evaluated. We hypothesized that methylphenidate can safely improve cognition in adults with epilepsy. We detail here the open-label follow-up to a double-blind, placebo-controlled, single-dose study. Methods: Thirty epilepsy patients entered a 1-month open-label methylphenidate trial after a double-blind phase. Doses were titrated according to clinical practice and patient tolerance, ranging 20-40 mg/day. Primary measures included: Conners' Continuous Performance Test (CPT), Symbol-Digit Modalities Test (SDMT), and Medical College of Georgia Memory Test (MCG). Secondary measures were: Beck Depression Inventory, 2nd Edition (BDI-II), Beck Anxiety Inventory, Apathy Evaluation Scale (AES), Stimulant Side-Effect Checklist, Adverse Events Profile, Quality of Life in Epilepsy-89 (QOLIE-89), and seizure frequency. Fourteen healthy, nonmedicated controls were tested concurrently. Results: Twenty-eight participants with epilepsy (13 men/15 women) completed the trial. Withdrawals occurred due to anxiety (n = 1) and fatigue (n = 1). Mean age was 36.4 years (range = 20-60). Epilepsy types were: focal (n = 21), generalized (n = 6), or unclassified (n = 1). Mean epilepsy duration was 12.3 years. Mean baseline seizure frequency was 2.8/month. There were significant improvements on methylphenidate for SDMT, MCG, CPT (the ability to discriminate between targets and nontargets [d 0 ] hits, hit reaction time standard deviation, omissions, and commissions), and QOLIE subscales (energy/fatigue, attention/concentration, memory, and language; paired t tests; p ≤ 0.002). BDI-II and additional subscales also improved, at a lower level of statistical significance. Effect sizes were moderate to large. Comparisons with untreated controls (n = 14) revealed greater improvement for epilepsy patients on omissions and commissions, with improvement trends on d 0 and hits. Seizure frequency did not increase with methylphenidate treatment (2.8/month vs. 2.4/month). Significance: Methylphenidate may be an effective and safe option for improving cognition and quality of life in epilepsy. Larger and longer double-blind, placebo-controlled clinical trials are needed.
Patients with epilepsy often suffer from inattention, memory impairment, and deficits in processing speed, which may be due to seizures, interictal epileptiform discharges, underlying brain disease, or antiepileptic drugs (AEDs). [1] [2] [3] [4] [5] [6] [7] [8] Cognitive and attentional symptoms in these patients may be managed by reducing seizures, decreasing AED polypharmacy, or switching to AEDs with fewer cognitive side effects, but this often does not result in resolution of the aforementioned deficits. 9 Cognitive rehabilitation has been used in patients with epilepsy, but systematic evaluation of this approach in this population is inadequate. [10] [11] [12] Thus, there is a need for well-validated treatments of cognitive deficits in patients with epilepsy.
The use of methylphenidate (MPH) and other stimulants to treat attention-deficit/hyperactivity disorder (ADHD) in patients with comorbid epilepsy has traditionally been a source of unease due to concerns that these medications may lower the seizure threshold. The U.S. Food and Drug Administration-approved packaging insert for these medications warns that they may increase the risk of seizures in patients with a history of epilepsy. However, evidence to support this concern is limited. A thorough review of the literature suggests that this concern appears to be primarily based on an early study demonstrating prolonging of artificially induced seizures in a rat model, 13 three case reports, [14] [15] [16] and a study of MPH overdose associated with seizures. 17 A study of extended-release MPH noted that high doses may be associated with an increase in daily seizures, but there were too few total seizures in the trial to confidently assess this. 18 In contrast, clinical studies in children [19] [20] [21] [22] have not observed an increased risk of seizures at commonly used doses. Recent reviews have concluded that MPH is the best-studied medication with the most data to support its safety and efficacy for use in children with ADHD and epilepsy, and that MPH is not associated with a clinically significant increase in risk for seizures. 4, 7, 9, 23, 24 Fewer data exist for the use of MPH in adults with epilepsy. Studies that do exist have generally corroborated the child data, demonstrating improvement in cognitive function without an increased risk of seizures. [21] [22] [23] 25 These studies, unfortunately, suffer from very small sample sizes, the lack of objective cognitive measures, and a lack of blinding. [21] [22] [23] Studies are needed that explicitly examine the impact of clinical MPH dosing schedules on measurable cognitive deficits in adult patients with epilepsy. Our preceding double-blind, placebo-controlled, single-dose study in this cohort demonstrated positive effects of MPH in patients with epilepsy, 26 but data are needed to demonstrate MPH's safety and efficacy for longer-term use in clinical dosing regimens in adult epilepsy patients with cognitive comorbidities. The present investigation is a 1-month, open-label follow-up to the aforementioned study. We hypothesized that MPH would improve scores on objective cognitive measures and on measures of quality of life without an increased risk of seizures.
Methods

Study design
This is the second portion of a two-part study investigating MPH in adults with epilepsy. Our study involved a doubleblind, placebo-controlled, single-dose phase followed by the presently described 1-month open-label trial. A graphic representation of the entire study is presented in Figure 1 . Participants completed a baseline visit, starting with informed consent, and then underwent physical examination and cognitive testing to introduce them to the test battery. No medication was given at this baseline visit. Visits 2, 3, and 4 constitute the double-blind portion of this study. At the completion of the double-blind, single-dose portion, participants were invited to participate in a 1-month open-label phase. Open-label, instant-release MPH was initiated after Visit 4, and participants started at either 5 mg twice daily (BID) or 10 mg BID based on tolerance of the blinded doses, clinician judgment, and participant preference. BID doses were given at approximately 8 AM and 1 PM. Doses were titrated toward the target dose of 20 mg BID. Final doses ranged between 10 mg BID and 20 mg BID based on patient tolerance. A healthy control group was included to assess for test-retest improvements, and these individuals completed the same neurocognitive testing at the same time intervals, but controls were not administered MPH. Reviews suggest that plasma levels are not helpful in determining an appropriate MPH dose; therefore, plasma levels were not drawn.
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Participants
The study was approved by the Stanford University Institutional Review Board (IRB), and signed informed consent was obtained from all subjects prior to participation. Subjects were primarily recruited through the Stanford Neurol- sample size of 30 patients with a test-retest reliability of 0.92 yielded 85% power (one-tailed) to detect a 10% difference in our outcomes based upon a 0.2 standard deviation (SD) of the difference score. Inclusion criteria included: epilepsy of any cause, cognitive complaints, stable AED doses that were not expected to change during the study, physical examination without concerning findings (e.g., cardiovascular), neurologist's judgment that the participant was clinically appropriate for this study, and capacity to consent. Exclusion criteria included: age <18 or >65 years, other major medical or neurological conditions (such as active malignancy or dementia) that may have interfered with cognition, status epilepticus within the year prior to entry, neurosurgery in the 6 months prior to entry, the use of non-AED medications that may have interfered with cognition, any allergy or condition that was considered a contraindication to MPH, a substance use disorder within the past year, suicide attempt within the past year, and pregnancy or breastfeeding. Healthy controls were recruited primarily from friends and families of participants with epilepsy. These individuals did not receive MPH during the trial, but completed the same testing at the same intervals throughout both phases of our study to control for improvement in the epilepsy cohort due solely to test-retest. Healthy controls were required to be between the ages of 18 and 65 years and free from neurological, medical, and psychiatric disorders that could interfere with cognition. In addition, healthy controls were required not to be taking any medications that might interfere with cognition, to be free from substance use, and to have no subjective cognitive complaints. All participants were asked to abstain from caffeine, food, and nicotine within 2 h of testing, and to avoid alcohol within 24 h of their visit.
Standard protocol approvals, registrations, and patient consents
This trial is registered on ClinicalTrials.gov under the following listing: Methylphenidate Treatment of Attention Deficits in Epilepsy (NCT02178995). This study was approved by the Stanford University IRB, and signed informed consent was obtained from all subjects prior to participation.
Procedure
After initiation of open-label MPH, the principal investigator (J.A.) followed up with participants by telephone each 2 One healthy control was lost to follow-up after Visit 2. hc, healthy controls; MPH, methylphenidate; pt, patients. Epilepsia ILAE week to assess efficacy, tolerability, and any adverse events. Medication strength was adjusted to find each individual's optimal dose, based on self-report of efficacy and side effects. Most patients began at 10 mg BID and, after 1 week, increased to 20 mg BID for the remainder of the trial. If side effects emerged, or if higher doses were less effective, doses were reduced in increments of 5 mg BID as needed. At the end of 1 month, patients again completed the neurocognitive battery and neuropsychiatric questionnaires. Seizure frequency was tracked by a month-long seizure diary. At the end of the trial, participants who wished to continue the medication were directed to follow up with their referring neurologist for further prescriptions. Healthy controls completed the same neurocognitive testing, as well as the Beck Depression Inventory, 2nd Edition (BDI-II), Beck Anxiety Inventory (BAI), and Apathy Evaluation Scale (AES), at the same intervals as the participants with epilepsy.
Measures
Neurocognitive battery
The neurocognitive battery consisted of the following measures: Symbol-Digit Modalities Test (SDMT), 29 Medical College of Georgia Paragraph Memory Test (MCG), 30 and Conners' Continuous Performance Test, 3rd Edition (CPT3). 31 The SDMT is a graphomotor substitution task shown to be sensitive to deficits in processing speed. The MCG is a measure of auditory memory (immediate recall) of short stories. Five different versions of the SDMT and MCG were administered in random order among the five visits to minimize practice effects.
The CPT3 is a computerized go/no-go task that presents an examinee with both target and nontarget stimuli and requires the examinee to press the space bar only when a target stimulus appears on the screen. The resulting CPT3 variable scores included the ability to discriminate between target and nontarget stimuli (d 0 ), response speed (hit reaction time), consistency in response speed (hit reaction time SD [HRTSD]), number of omissions and commissions, and total hits.
Quality of Life in Epilepsy
The Quality of Life in Epilepsy (QOLIE-89) 32 is a selfreport questionnaire designed to assess the impact of epilepsy on various life domains including physical health, occupational functioning, emotional well-being, and attention/concentration. As the questionnaire is specific to those with epilepsy, healthy controls did not complete the QOLIE-89.
Seizure diary
A blank seizure calendar was provided to participants with epilepsy at each visit. Participants were asked to document, if any, each seizure they experienced and describe the type of seizure it was. Baseline seizure frequency was determined with a retrospective 28-day calendar filled out at the first visit based on patient and family report in conjunction with a review of medical records. A new weekly seizure calendar was filled out during the double-blind visit to monitor any events following enrollment. This seizure calendar was continued during the month-long open-label trial. The raw number of seizures recorded was then converted to a rate of seizures per 28 patient days.
Adverse events profile and stimulant side effect checklist
The Liverpool Adverse Events Profile (AEP) 33 allows the respondent to document the severity of common AEDrelated side effects from "never a problem" to "always or often a problem" within the past month. The Stimulant Side Effect Checklist (SSC) 34 is a self-report questionnaire that assesses the absence or presence of common stimulantrelated side effects within the past week. Respondents are asked to rate behaviors from zero (absent) to nine (serious) to indicate the severity and frequency of each behavior. As healthy controls were neither on AEDs nor stimulants, they did not complete these questionnaires.
Emotional functioning
The BDI-II 35 is a 21-item self-report questionnaire that assesses depressive symptoms. Similarly, the BAI 36 is a 21-item form used to assess anxiety. The AES 37 is an 18-item scale administered in this study as a self-report questionnaire. Participants are prompted to rate symptoms related to apathy on a scale ranging from "not at all" to "a lot."
Primary outcome variables for our study were: SDMT total correct score, MCG total score, HRTSD, and d 0 . Secondary outcome variables included: omissions, commissions, total hits, and QOLIE-89 total score and subscales attention/concentration, memory, language, and energy/fatigue. Adverse events were monitored using the AEP and SSC as well as participant interview. Seizure frequency per 28 patient days was the major safety measure. We hypothesized that MPH would improve scores on these measures of attention, memory, and processing speed, with no significant difference between the two doses and no increase in seizures.
Statistical analyses
Planned paired t-tests on scores from Visits 1 and 5 for all measures were performed separately for epilepsy patients and healthy controls. Complete datasets were compared; there was no adjustment for missing data. Although these comparisons were performed across tasks, given the preliminary nature of this report, twoway analyses of variance were also conducted to analyze any interaction effects between participants with epilepsy and healthy control volunteers on those measures administered to both groups.
Results
Thirty participants with epilepsy and 14 healthy controls were enrolled. Two epilepsy patients withdrew due to anxiety (n = 1) and fatigue (n = 1); no healthy controls withdrew. The demographics for those who completed the trial, including gender, age, educational level, epilepsy duration, seizure type, and etiology are given in Table 1 . A paired t-test did not reveal any significant differences between participants with epilepsy and healthy control volunteers based on age and education. Mean MPH dose at completion of the trial was 38.2 mg/day. AED doses did not change during the study. Table 2 summarizes the CPT3 raw scores obtained by both groups on Visits 1 and 5. Statistically significant results (p < 0.05) are in boldface; trends are also noted. Both participants with epilepsy and healthy controls improved across multiple variables, including d 0 , HRTSD, and omissions. Participants with epilepsy, but not healthy controls, showed an improvement in the rate of commissions. Interaction effects suggesting that participants with epilepsy improved beyond healthy controls were observed for omissions and commissions (p < 0.05) as well as a trend for d 0 and number of hits (p < 0.08). For these interaction effects, effect sizes were moderate.
Neurocognitive measures
A post hoc analysis undertaken to better evaluate individual responses examined CPT3 d 0 scores in both groups. This measure was selected because the CPT3 normative dataset is significantly larger than the MCG or SDMT, and CPT3 d 0 is a primary measure used to characterize ADHD. Abnormality was defined as scores reflecting performance poorer than 1 SD below the mean (mean = À3.1, SD = 0.9). 31 No control subjects had CPT3 d 0 scores in the impaired range; six epilepsy subjects (22%) did. Using an improvement of 1.1 U as clinically significant, 31 we examined individual changes following MPH (or, in the case of healthy controls, on reexamination). As is common in the neuropsychological literature, p < 0.10 was used to establish the change criterion. Of the six epilepsy patients with impaired baseline CPT3 d 0 scores, four (60%) demonstrated significant improvement associated with MPH. Five additional epilepsy patients without impaired baseline scores (19%) showed significant improvement following treatment. One control subject (7%) showed a significant improvement on reevaluation despite having normal baseline performance. In examining the relationship between improvement in d 0 with scores for the SDMT and MCG, we observed no relationship with SDMT (r = 0.1), but a significant correlation with MCG (r = À0.33, p = 0.036). Table 2 also displays the results of the SDMT and MCG. Both the MPH group and healthy controls showed significantly improved performance on the SDMT and MCG. A two-way analysis of variance did not demonstrate any significant interaction effects between the two groups.
QOLIE scores
QOLIE-89 scores are displayed in Table 3 . QOLIE-89 total score significantly improved between Visits 1 and 5 for participants with epilepsy. Significant improvements were also found among the scores of the following QOLIE-89 subscales: attention/concentration, memory, language, energy/fatigue, health perceptions, overall quality of life, role limitations (physical), work/driving/social, and health discouragement. Effect sizes were large. Table 4 displays the results of the BDI-II, BAI, AES, AEP, and SSC. Significant improvements were seen on the BDI-II for both participants with epilepsy and healthy controls. AES scores improved for epilepsy patients only. Interestingly, both the SSC and AEP improved between Visits 1 and 5. No interaction effects were noted for the BDI-II, BAI, or AES.
Neuropsychiatric questionnaires
Adverse effects/tolerability
MPH was generally well tolerated, with 25 of 30 participants reaching and tolerating the full 20 mg BID dose. Of the remainder, one preferred 15 mg BID, whereas two found optimal benefit at 10 mg BID. Two participants withdrew at 10 mg BID, one due to fatigue and one due to anxiety, despite having previously tolerated all blinded doses. Other reported side effects not leading to withdrawal included: anxiety (n = 2, 20 mg), insomnia (n = 1, 10 and 20 mg), sore throat (n = 1, 20 mg), reduced appetite (n = 2, 20 mg), jitteriness (n = 3, 20 mg), and vivid dreams (n = 1, 20 mg). These either resolved by the end of the trial or were deemed tolerable by the participant. There was no significant difference in participant heartrate or blood pressure between the start and end of the trial (data not shown). Twenty-one of 30 participants elected to continue the medication after the completion of the trial. 
Seizure frequency
No significant change in seizure frequency for participants with epilepsy was present when comparing baseline to the open-label period (2.8 vs. 2.4 seizures per 28 days, respectively, p = 0.274). This was also not significantly different from the rate observed in our double-blind study (data not shown).
Discussion
Both participants with epilepsy and healthy controls improved across multiple cognitive variables. Participants with epilepsy showed greater improvements than healthy controls on measures of attention (i.e., commissions and omissions with trends for d 0 and hits), and post hoc analysis indicates that for many participants, these changes were clinically significant. Improvement in attention as measured by decreasing values of d 0 correlated with improvement in memory scores, but not with processing speed, although larger samples will be necessary to investigate this more thoroughly. Epilepsy patients also demonstrated significant improvements in quality of life, with large effect sizes. Crucially, seizure frequency was not affected by doses of MPH up to 20 mg BID. Although participants showed . Generally, 0.01 = small, 0.06 = medium, and 0.14 = large effect sizes. improvements on psychiatric measures such as the BDI-II, these did not separate from unmedicated healthy controls. Scores on the stimulant side effects checklist and the adverse events profile both improved between Visits 1 (baseline) and 5 (end of open label). Although it is counterintuitive that SSC scores decreased with the addition of a stimulant, it is conceivable that this represents a more generalized subjective sense of improvement driven primarily by improved quality of life or by placebo effect. Taken together, these data suggest that instant-release MPH may be a safe and effective medication for treating cognitive difficulties in adult patients with epilepsy, and that improvement on some cognitive variables was greater than can be explained by test-retest improvement alone. ADHD is estimated to affect 1-5% of adults 38 and 3-5% of children. 39 Although large epidemiological studies of adults with epilepsy are not available, 36% of children with epilepsy suffer from ADHD, making it the most common comorbid disorder in childhood epilepsy. A functional magnetic resonance imaging study by Bechtel and colleagues 40 postulated that ADHD-like symptoms, with or without epilepsy, likely share a common neural network, and noted a similar pattern of neural activation associated with responsiveness to MPH, suggesting there may be little difference in ADHD with and without epilepsy. As such, it is reasonable to expect that stimulants would be effective in ameliorating cognitive issues associated with epilepsy, even in the absence of premorbid ADHD. Given how common such deficits are, their impact on patient quality of life, 41 and the absence of alternative validated treatments, adjunctive MPH, if effective as some child studies suggest, 42 could represent a relatively simple clinical intervention that could yield meaningful improvements in patient functioning and quality of life.
Strengths and Limitations
Important strengths of this study include its prospective design, a larger sample size than prior similar investigations, the use of clinical prescribing practices, and the use of established, standardized cognitive measures across multiple cognitive domains. Other strengths include a clinically diverse population and use of subjective as well as objective measures. The study was designed to enhance overall generalizability. The use of individuals' optimal dose for comparison is consistent with literature suggesting that individual responses are idiosyncratic and not well predicted by serum level or dosing by weight. However, the final analyzed sample is still relatively small, and larger studies would help corroborate the results. Additional studies with longer duration are also needed. Another important limitation of this portion of the study is that it was unblinded, although the preceding single-dose portion was doubleblind and placebo-controlled. The use of healthy controls as a control group is an important limitation, as a control group of patients with epilepsy who did not receive MPH would be expected to be more similar at baseline to our active group. Furthermore, healthy individuals are known to show greater test-retest improvement than patients with epilepsy. 43 Thus, our use of healthy controls as a control group may lead to an underestimation of the effects of MPH. A ceiling effect in the healthy control group might obscure a practice effect that would otherwise be found. However, the only measure with a clear possible ceiling effect is the MCG, as the CPT3 and SDMT are speed/time based and performance improvements on these can be detected regardless of baseline performance levels. Additionally, the criterion of significant improvement for CPT3 d 0 was based upon healthy normative subjects, and the improvement in the healthy control group (7%) roughly corresponds to the expected chance improvement level under the null hypothesis. It is also possible that specific subgroups of epilepsy patients (e.g., traumatic brain injury and poststroke) may have different responses than other epilepsy patients, and our sample size is too small for such . Generally, 0.01 = small, 0.06 = medium, and 0.14 = large effect sizes. subgroup analyses. Individuals who perceived some benefit from the blinded portion of our study may have been more likely to elect to continue on to the openlabel, which could create selection bias for MPH responders. However, as only two individuals completed the double-blind but did not choose to continue to the open label, this effect is likely small. Finally, the large majority of our participants preferred the 20 mg BID dose, despite side effects, but our protocol did not allow for assessment of higher doses, which might be more effective in some patients.
Summary and Future Directions
MPH may be a safe and effective treatment for cognitive difficulties experienced by adult patients with epilepsy. Additional double-blind, placebo-controlled clinical trials using standard clinical dosing procedures and standardized, repeatable cognitive measures with larger sample sizes and longer treatment periods are needed.
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